Although EGFR mutations itself is not a predictor for a better survival in adenocarcinoma patients as shown in both the present study and a previous study (Kosaka et al, 2004), EGFR mutations were good predictor of the clinical benefit with patients with gefitinib treatment in such patients. This evidence concerns the gene EGFR and adenocarcinoma.